About Us
Science Programs
Pipeline
Clinical Trials
Careers
cONTACT
Resources
Corporate Presentation
Posters & pRESENTATIONS
MEDIA
Events
News & press releases
Investors
Overview
Stock Information
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Financials & SEC FILINGS
Sec Filings
Quarterly Results
cORPORATE GOVERNANCE
Management Team
Board of Directors
Committee Composition
Governance Documents
Resources
Presentations
March 9, 2022
Corporate Presentation - May 2022
VIEW Resource
r
November 11, 2021
Research and Development Day Presentation - November 2021
VIEW Resource
r
Milademetan
Posters & Presentations
AACR 2022
Mrinal M. Gounder, Gary K. Schwartz, Robin L. Jones, Sant P. Chawla, Victoria S. Chua-Alcala, Silvia Stacchiotti, Andrew J. Wagner, Gregory M. Cote, Robert G. Maki, Hanna Kosela-Paterczyk, Dale R. Shepard, Naisargee Shah, Richard Bryce, Robert C. Doebele, Shreyaskumar Patel
MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with dedifferentiated liposarcoma
VIEW Resource
r
AACR 2022
Ecaterina E. Dumbrava, Glenn J. Hanna, Gregory M. Cote, Thomas Stinchcombe, Melissa Johnson, Christopher T. Chen, Siddhartha Devarakonda, Naisargee Shah, Feng Xu, Robert C. Doebele, Mrinal M. Gounder
MANTRA-2: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53 wild-type and MDM2-amplified advanced or metastatic solid tumors
VIEW Resource
r
AACR 2022
Vijaya G. Tirunagaru, Feng Xu and Robert C. Doebele
Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors
VIEW Resource
r
AACR-NCI-EORTC 2021
Vijaya G. Tirunagaru, PH.D.
MDM2gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan
VIEW Resource
r
AACR-NCI-EORTC 2021
Vijaya Tirunagaru, Ph.D.
The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer
VIEW Resource
r
AACR-NCI-EORTC 2021
Varsha Ananthapadmanabhan, Ph.D.
Milademetan is a potent, murine double minute 2 (MDM2) inhibitor, highly active in TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) cell lines
VIEW Resource
r
IASLC 2021 World Conference on Lung Cancer
Lynn Heasley, Ph.D.
The MDM2/p53 axis is a therapeutic vulnerability in malignant pleural mesothelioma
VIEW Resource
r
EORTC-NCI-AACR 2020
Mrinal M. Gounder
Milademetan (DS-3032b or RAIN-32), an Oral MDM2 Inhibitor, in Well-Differentiated/Dedifferentiated Liposarcoma: Results From a Phase 1 Study in Patients With Solid Tumors or Lymphomas
VIEW Resource
r
ASH 2019
Courtney D. DiNardo
A Phase 1 Dose-Escalation Study of Milademetan in Combination With 5-Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
VIEW Resource
r
ASH 2019
Naval Daver
A Phase 1 Study of Milademetan in Combination With Quizartinib in Patients With Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
VIEW Resource
r
ESMO 2019
Toshio Shimizu
A Phase 2 biomarker-driven study evaluating the clinical efficacy of MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
VIEW Resource
r
Rad52
posters & presentations
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
Nucleic Acids Res. 2016 May 19;44(9):4189-99
VIEW Resource
r
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
Cell Rep. 2018 Jun 12;23(11):3127-3136.
VIEW Resource
r
%20(1).png)
